Updated PBAC Outcomes for November 2016
Page last updated: 7 February 2017
Subsequent to the deferral at the November 2016 PBAC meeting, the PBAC recommended the PBS listing of ivacaftor for treatment of cystic fibrosis CF in patients over the age of 2 years who have a G551D mutation or other class III gating mutations in the CFTR gene.
More information is available on the Recommendations by the PBAC - November 2016 page - Positive Recommendations.
